Engimmune Therapeutics is a platform and product development company engineering next-generation T cell receptor therapies.
Engimmune Therapeutics has raised $15.8M in total funding. The most recent round was Seed. The last funding was announced in May 2022.
Engimmune Therapeutics's investors include Novo Holdings, Pureos Bioventures, BaseLaunch, Kinled Holding.
Engimmune Therapeutics is headquartered in Basel, Switzerland.
Engimmune Therapeutics is a platform and product development company engineering next-generation T cell receptor therapies.
Engimmune Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Engimmune Therapeutics — Funding & Investors." VCBacked, May 3, 2022, https://www.vcbacked.co/company/engimmune-therapeutics. Accessed August 8, 2026.
VCBacked. (2022). Engimmune Therapeutics — Funding & Investors. Retrieved August 8, 2026, from https://www.vcbacked.co/company/engimmune-therapeutics
{{cite web |title=Engimmune Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/engimmune-therapeutics |website=VCBacked |access-date=August 8, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated